130369-04-9

Basic information

• Product Name: Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI);N-Boc-3-methylene-cyclobutanamine;CarbaMic acid, N-(3-Methylenecyclobutyl)-, 1,1-diMethylethyl ester;1-(Boc-amino)-3-methylenecyclobutane;tert-butyl (3-methylidenecyclobutyl)carbamate;(3-Methylenecyclobutyl)carbamic acid 1,1-dimethylethyl ester;tert-Butyl (3-methylenecyclobutyl)
• CAS NO: 130369-04-9
• Molecular Formula: C₁₀H₁₇NO₂
• Molecular Weight: 183.24748
• Product Categories: N-BOC
• Mol File: 130369-04-9.mol

Chemical Properties

• Melting Point: 95-100°C
• Boiling Point: 263.8 °C at 760 mmHg
• Flash Point: 113.3 °C
• Appearance: /
• Density: 1 g/cm³
• Refractive Index: 1.474
• PKA: 12.22±0.20(Predicted)
• CAS DataBase Reference: Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI)(130369-04-9)
• EPA Substance Registry System: Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI)(130369-04-9)

Safety Data

• Hazard Codes: N
• Statements: 50
• Safety Statements: 61
• RIDADR: UN 3077 9 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 130369-04-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI) is used as an intermediate in the synthesis of pharmaceuticals for its potential role in organic chemical reactions.
Used in Agrochemical Synthesis:
In the agrochemical industry, Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI) is utilized as an intermediate in the production of various agrochemicals, contributing to the development of effective pest control agents.
Used in Laboratory Research:
Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI) is also employed in laboratory research for studying its chemical properties and potential applications in various fields, including the development of new chemical processes and products.
Industrial Applications:
Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI) may have other industrial applications, although specific uses are not detailed in the provided materials. Its versatility in organic chemical reactions suggests potential for broader use in chemical manufacturing and related industries.
Safety Considerations:
It is crucial to handle Carbamic acid, (3-methylenecyclobutyl)-, 1,1-dimethylethyl ester (9CI) with care and follow proper safety guidelines due to its potential hazards, ensuring the safety of individuals and the environment.

InChI:InChI=1/C10H17NO2/c1-7-5-8(6-7)11-9(12)13-10(2,3)4/h8H,1,5-6H2,2-4H3,(H,11,12)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 15760-36-8 3-methylenecyclobutane-1-carboxylic acid 
• 100114-49-6 3-methylenecyclobutylamine 
• 15760-35-7 3-methylenecyclobutanecarbonitrile 
• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 75-65-0 tert-butyl alcohol 
• 6399-81-1 triphenylphosphine hydrobromide 

Downstream Products

• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 1427329-27-8 (3-hydroxy-3-methyl-cyclobutyl)-carbamic acid tert-butyl ester 
• 154748-63-7 tert-butyl ((1s,3s)-3-hydroxycyclobutyl)carbamate 
• 1033718-11-4 cis-3-[(tert-butoxycarbonyl)(methyl)amino]cyclobutyl methanesulfonate 
• 1392803-14-3 tert-butyl (trans-3-aminocyclobutyl)methylcarbamate 
• 1420270-95-6 tert-Butyl spiro[2.3]hexan-5-ylcarbamate 

Relevant articles and documents

1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS

A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Synthesis of novel non-natural spiro[2.3]hexane amino acids, the conformationally restricted analogs of γ-aminobutyric acid

3-Methylenecyclobutanecarboxylic acid and its methyl ester were used as the starting compounds for the synthesis of new spiro[2.3]hexane amino acids, the conformationally rigid analogs of γ-aminobutyric acid, namely, 5-aminospiro[2.3]hexanecarboxylic and 5-amino-spiro[2.3]hexanephosphonic acids, promising modulators of GABAergic cascades in the human central nervous system. The methods developed for the synthesis of the target amino acids are based on the reactions of catalytic [1+2] cycloaddition of diazoacetic and diazophosphonic esters to 3-substituted methylenecyclobutanes, as well as on a modified Curtius reaction for the transformation of a carboxy group to the amine one.

Tigecycline derivatives (by machine translation)

The invention belongs to the medicinal technical field, and in particular relates to a tigecycline derivative of general formula (I), a pharmaceutically acceptable salt, precursor drug, solvate or isomer thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R

Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION

The invention provides novel compounds having the general formula: formula (I) wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUND

The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.

9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS

The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.

PYRROLOPYRIMIDINE AND PURINE DERIVATIVES

The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.